Co-Development Opportunities Tagworks is advancing TGW101 with IND clearance and a first-in-human Phase 0/1 program, plus an investigator-initiated trial with Radboudumc for TGW211, signaling strong potential for co-development, licensing, or strategic partnerships to accelerate ADC and targeted radiotherapy programs.

US Collaboration Potential Headquartered in the Netherlands with active U.S. operations, Tagworks can engage U.S.-based CROs, contract manufacturers, and clinical sites to accelerate early clinical development and broaden access to the U.S. oncology market.

Targeted Platform Edge TAG72 is a surface-expressed non-internalizing target, enabling Click-to-Release ADCs and radiopharmaceuticals; this unique biology creates opportunities for partnerships with imaging firms and radiopharma developers seeking companion diagnostics or theranostic collaborations.

Industry Partnerships Active participation in PEGS Summit Europe and other antibody-therapy conferences provides direct access to potential pharma, academic partners, and CRO networks for deal origination and co-development conversations.

Funding Readiness With funding around $65M and revenue in the $10–25M range, Tagworks demonstrates financial backing to support milestone-driven collaborations, licensing discussions, and joint development ventures with larger oncology players.